The Wall Street Journal news department was not involved in the creation of this content.

PRESS RELEASE
February 24, 2014, 8:05 a.m. ET

InVivo Therapeutics Names Thomas R. Ulich, MD as Its New Chief Scientific Officer

Email
Printer
Friendly
Share:

facebook ↓ More
smaller Text larger

CAMBRIDGE, Mass.--(BUSINESS WIRE)--February 24, 2014--

InVivo Therapeutics Holdings Corp. (NVIV) today announced appointment of Thomas R. Ulich, MD as Chief Scientific Officer, effective February 24, 2014.

Dr. Ulich previously served as Executive Vice-President of Research and Development of ConjuChem Biotechnologies from 2006 - 2010. Prior to that, he served as Senior Vice-President of Research and Development for Alnylam Pharmaceuticals from 2003-2004. Before that he served at Amgen as Vice-President of Preclinical Development from 1993-2001 and as Vice-President of Preclinical Development and Protein Therapeutics from 2001 -- 2003. Dr. Ulich has a BA from Dartmouth College and an MD from UCLA Medical School. He has medical board certification from the American Board of Anatomic Pathology, the American Board of Clinical Pathology, and the American Board of Immunopathology.

Mark Perrin, InVivo's Chief Executive Officer said, "Tom Ulich brings to InVivo a broad scientific background and expertise that will be invaluable as we build our biomaterials portfolio."

http://online.wsj.com/article/PR-CO-...24-905672.html